Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
IBC Pharmaceuticals, Inc.
C C A A A B A C A A C C A C C C A B A C B A
C07K C07K A61P A61K A61P B82Y A61P C07K A61K A61P C07K C07K A61P C07K C07K C07K A61P B82Y A61P C07K B82Y A61P
additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional additional additional inventional inventional inventional inventional inventional inventional
Edmund A. William J. David M. Chien-Hsing
Rossi McBride Goldenberg Chang